Publication

Population Pharmacokinetics and Exposure-Response Analysis of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia Patients With NPM1 Mutation

This study evaluated how the leukemia drug ziftomenib behaves in the body and whether different…

CertaraMay 7, 2026

Publication

Population Pharmacokinetic Modeling and Exposure-Response Analyses of Nemtabrutinib in Patients With Hematologic Malignancies

Population pharmacokinetic (PopPK) and exposure-response modeling were used to support the clinical development of nemtabrutinib,…

CertaraMay 7, 2026

Publication

Understanding quantitative effects of anti-amyloid therapies on tau biomarkers and functional outcome

QSP modeling reveals how anti-amyloid therapies impact tau biomarkers and cognitive outcomes in Alzheimer’s disease.

CertaraMay 4, 2026

Poster

Modeling CAR-T Outcomes in Multiple Myeloma

Learn how QSP modeling predicts CAR-T therapy outcomes, identifies patient-specific response drivers, and supports multi-antigen…

CertaraMay 4, 2026

Poster

Modeling T-cell Exhaustion in Immunotherapy

Discover how QSP modeling predicts T-cell exhaustion, relapse risk, and optimal dosing strategies for T-cell…

CertaraMay 4, 2026

Poster

Modeling Hematopoiesis in MDS and AML with QSP

Discover a mechanistic QSP platform model of hematopoiesis to evaluate therapies in MDS and AML,…

CertaraMay 1, 2026

Poster

IO Simulator: A QSP Platform for Immuno-Oncology

This poster showcases how IO Simulator predicts immunotherapy response and supports combination design and biomarker…

CertaraApril 30, 2026

Blog

From Models to Impact: What QSPC 2026 Revealed About the Future of Drug Development

Explore Certara’s insights from QSPC 2026, including virtual patients, regulatory adoption, AI in QSP, and…

CertaraApril 28, 2026

Blog

Top 10 Benefits of Simcyp® Simulator for Drug Development

JTVCdGVhbV9qdW1wX2xpc3QlNUQ= April 23, 2026 Physiologically based pharmacokinetic (PBPK) modeling has evolved from an emerging methodology…

CertaraApril 23, 2026

Blog

ADC Dose Optimization: Applying Model-Informed Strategies in Development

Explore ADC dose optimization using model-informed strategies to balance efficacy and safety across antibody drug…

CertaraApril 22, 2026

Modeling and Simulation

Population Pharmacokinetics and Exposure-Response Analysis of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia Patients With NPM1 Mutation

Population Pharmacokinetic Modeling and Exposure-Response Analyses of Nemtabrutinib in Patients With Hematologic Malignancies

Understanding quantitative effects of anti-amyloid therapies on tau biomarkers and functional outcome

Modeling CAR-T Outcomes in Multiple Myeloma

Modeling T-cell Exhaustion in Immunotherapy

Modeling Hematopoiesis in MDS and AML with QSP

IO Simulator: A QSP Platform for Immuno-Oncology

From Models to Impact: What QSPC 2026 Revealed About the Future of Drug Development

Top 10 Benefits of Simcyp® Simulator for Drug Development

ADC Dose Optimization: Applying Model-Informed Strategies in Development

Newsletter sign up

Quick links

Solutions

Contact